stockrowLantheus Holdings, Inc.
LNTH Healthcare Drug Manufacturers Specialty & Generic
Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.
- Revenue
- +1.54%
- EPS
- −17.1%
- Free cash flow
- +7.71%
- Total debt
- +0.52%
Quarter to September 2026, against a year earlier
Follow LNTH
Alert me
Lantheus Holdings, Inc. (LNTH) Revenue
Lantheus Holdings, Inc.'s revenue for fiscal 2025 was $1.5B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $1.6B. Over the past ten years it has ranged from $293.5M (fiscal 2015) to $1.5B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 5 consecutive fiscal years. Lantheus Holdings, Inc. ranks 15th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $1.5B | 0.50% |
| FY2024 | $1.5B | 18.32% |
| FY2023 | $1.3B | 38.65% |
| FY2022 | $935.1M | 119.91% |
| FY2021 | $425.2M | 25.28% |
| FY2020 | $339.4M | (2.28%) |
| FY2019 | $347.3M | 1.15% |
| FY2018 | $343.4M | 3.62% |
| FY2017 | $331.4M | 9.78% |
| FY2016 | $301.9M | 2.86% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $389.9M | 0.45% |
| Jun 2026 | $388.2M | 2.87% |
| Mar 2026 | $377.3M | (7.24%) |
| Dec 2025 | $406.8M | 5.93% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| RDY Dr. Reddy's Laboratories Ltd compare | $3.3B |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $3.2B |
| HIMS Hims & Hers Health, Inc. compare | $2.6B |
| ALKS Alkermes plc compare | $1.8B |
| LNTH Lantheus Holdings, Inc. | $1.6B |
| SUPN Indivior Pharmaceuticals Inc. compare | $1.4B |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $946.0M |
| LQDA Liquidia Corporation compare | $450.9M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | $87.4M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on LNTH
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement